Skip to main content

Table 2 Treatment adverse events (n = 14 pts)

From: Radiochemoimmunotherapy with intensity-modulated concomitant boost: interim analysis of the REACH trial

adevers events
(AEs), n = 14
severity (CTC v. 3) grade   
  I II III IV V
acneiforme skin rash 5 (35.7%) 9 (64.3%) 1 (7.1%)   
conjunctivitis   1 (7.1%)    
skin fissures 1 (7.1%) 1 (7.1%)    
mucositis 2 (14.3%) 8 (57.1%) 4 (28.6%)   
dysphagia 5 (35.7%) 7 (50%) 1 (7.1%)   
weight loss 1 (7.1%) 1 (7.1%)    
dermatitis 2 (14.3%) 6 (42.9%) 2 (14.3%)   
xerostomia 8 (57.1%) 5 (35.7%)    
laryngeal oedema 3 (21.4%)     
anemia   1 (7.1%)    
leukopenia    1 (7.1%)   
thrombopenia     1 (7.1%)  
fever 1 (7.1%) 1 (7.1%)    
hyperkalaemia 1 (7.1%)     
hypokalaemia    2 (14.3%)   
hypomagnesiaemia 3 (21.4%)     
nausea 5 (35.7%)     
oedema 7 (50%)     
diarrhoea 3 (21.4%)     
constipation 5 (35.7%)     
Serious adverse events (SAEs)     
skin abscess    1 (7.1%)   
arterial embolism    1 (7.1%)   
septic shock    1 (7.1%)   
anaphylactic reaction   1 (7.1%)   
hospital admission due to tonsillitis 1 (7.1%)   
death due to progressive metastatic disease    1 (7.1%)